Cargando…

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Potestio, Luca, Ruggiero, Angelo, Fabbrocini, Gabriella, Martora, Fabrizio, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166089/
https://www.ncbi.nlm.nih.gov/pubmed/37168605
http://dx.doi.org/10.2147/PTT.S407647
_version_ 1785038372997169152
author Potestio, Luca
Ruggiero, Angelo
Fabbrocini, Gabriella
Martora, Fabrizio
Megna, Matteo
author_facet Potestio, Luca
Ruggiero, Angelo
Fabbrocini, Gabriella
Martora, Fabrizio
Megna, Matteo
author_sort Potestio, Luca
collection PubMed
description Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of biological drugs and small molecules revolutionized the treatment options showing promising results in terms of safety and effectiveness, some limitations remain. Thus, there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. In this scenario, deucravacitinib, an oral small molecule which selectively inhibits Tyrosine Kinase 2, may represent a promising weapon in psoriasis management. The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis.
format Online
Article
Text
id pubmed-10166089
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101660892023-05-09 Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature Potestio, Luca Ruggiero, Angelo Fabbrocini, Gabriella Martora, Fabrizio Megna, Matteo Psoriasis (Auckl) Review Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of biological drugs and small molecules revolutionized the treatment options showing promising results in terms of safety and effectiveness, some limitations remain. Thus, there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. In this scenario, deucravacitinib, an oral small molecule which selectively inhibits Tyrosine Kinase 2, may represent a promising weapon in psoriasis management. The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis. Dove 2023-05-04 /pmc/articles/PMC10166089/ /pubmed/37168605 http://dx.doi.org/10.2147/PTT.S407647 Text en © 2023 Potestio et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Potestio, Luca
Ruggiero, Angelo
Fabbrocini, Gabriella
Martora, Fabrizio
Megna, Matteo
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
title Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
title_full Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
title_fullStr Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
title_full_unstemmed Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
title_short Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
title_sort effectiveness and safety of deucravacitinib for the management of psoriasis: a review of the current literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166089/
https://www.ncbi.nlm.nih.gov/pubmed/37168605
http://dx.doi.org/10.2147/PTT.S407647
work_keys_str_mv AT potestioluca effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature
AT ruggieroangelo effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature
AT fabbrocinigabriella effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature
AT martorafabrizio effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature
AT megnamatteo effectivenessandsafetyofdeucravacitinibforthemanagementofpsoriasisareviewofthecurrentliterature